SeaStar Medical Reports Third Quarter 2026 Financial Results - SEASTAR MEDICAL HOLDING CORP

Financial Performance:

• Q3 2026 net revenue reached approximately $635,000, a 247% increase year-over-year from $183,000 in Q3 2025.
• Nine-month net revenue exceeded $1.7 million, doubling year-over-year, putting the company on track to surpass the $2 million annual guidance for Quell Immune sales.
• Gross profit margin remained robust at over 90% for the quarter, consistent with previous quarters.
• Operating expenses increased to $5.2 million in Q3 2026 compared to $3.7 million in Q3 2025, driven primarily by higher R&D costs associated with clinical trials.
• Net loss for Q3 2026 was approximately $4.5 million ($1.03 per share), an improvement from the $3.5 million loss ($1.30 per share) reported in Q3 2025.
• Cash balance stood at approximately $4 million as of September 30, 2026, down from $12 million at year-end 2025; this figure excludes $3.3 million in gross proceeds from warrant exercises processed in October 2026.

Guidance and Future Outlook:

• Patient enrollment for the pivotal Neutralized AKI trial is projected to complete by mid-2027 due to strict inclusion/exclusion criteria, with a cautious adjustment from previous timelines.
• The company anticipates submitting the final PMA module approximately nine months after enrollment completion, potentially in Q1 2028.
• Management expects a "priority review" for the PMA upon submission of the final clinical data module, facilitated by the FDA's Breakthrough Device Designation.
• Full-year 2026 revenue guidance remains at $2 million, with management confident of exceeding this target based on current momentum.
• 2027 guidance will be provided in early 2027, reflecting continued focus on pediatric AKI adoption and potential adult AKI market entry.
• Strategic focus for 2027 involves targeting the top 50 pediatric medical centers, expanding from the current 20 existing customers to 10+ new additions planned for the remainder of 2026.

Business Segments and Product Lines:

• Quell Immune: Sales growth driven by strong demand in the ultra-rare pediatric AKI market; 247% revenue surge indicates deepening market penetration.
• Pivotal Clinical Trial (Neutralized AKI): Currently enrolled 251 of 339 patients (74%) in the adult AKI on CRRT study; the primary endpoint is a composite of mortality or dialysis dependence at 90 days.
• PMA Strategy: Utilizing a modular submission approach, with the first module already submitted to the FDA to accelerate review cycles prior to final clinical data availability.
• New Indications: Received FDA Breakthrough Device Designation for adult sepsis/septic conditions, representing the seventh indication for the SCD platform.
• Regulatory Milestones: FDA confirmed satisfaction of mandatory post-approval SAVE registry requirements, and CMS assigned ICD-10 PCS codes to facilitate hospital billing.

Market and Competitive Landscape:

• Clinical Data Momentum: Late-breaking presentation at ASN Kidney Week 2026 showed statistically significant higher survival rates for Quell Immune-treated pediatric AKI patients (65% 90-day survival vs. 47% in the control cohort, p=0.043).
• Market Position: Quell Immune is the only therapy for ultra-rare pediatric AKI, addressing a critical unmet need in critical care nephrology.
• Competitive Advantage: The SCD platform's ability to modulate inflammation without broadly suppressing the immune system distinguishes it in sepsis and AKI treatment.
• Adoption Barriers Removed: The removal of the mandatory SAVE registry requirement and the addition of billing codes are expected to streamline hospital adoption processes.

Risks and Challenges:

• Enrollment Delays: Strict trial eligibility criteria have moderated enrollment rates, extending the completion timeline to mid-2027.
• Clinical Uncertainty: Success of the pivotal AKI trial is not guaranteed; results are critical for adult AKI approval and broader commercial viability.
• Cash Runway: Significant cash burn from R&D activities reduced the cash balance from $12 million to $4 million in a single year, though recent warrant exercises will add liquidity.
• Market Size: The ultra-rare nature of the pediatric AKI condition limits the immediate revenue ceiling, requiring careful expansion into larger adult populations.
• Regulatory Dependency: PMA approval and timeline are heavily dependent on FDA review speed and the outcome of the pivotal trial.

Management Commentary and Tone:

• Tone was described as "optimistic yet cautious," emphasizing the critical need for rigorous data despite enrollment delays.
• Management expressed strong confidence in the SCD platform's disease-agnostic potential across multiple life-threatening conditions.
• CEO Eric Schlorf and CMO Dr. David Chung highlighted the emotional and clinical imperative to save lives in the face of high-mortality conditions like sepsis and AKI.
• Management acknowledged the disappointment regarding the extended trial timeline but prioritized study integrity and optimized outcomes over speed.

Analyst Questions and Answers:

• David Bouts (Zacks Small Cap Research): Asked about the updated timeline from enrollment to PMA filing and patient treatment volumes.
  • Answer: Filing the final PMA module is expected ~9 months post-enrollment completion. Current customers are primarily repeat users; revenue flatness vs. Q2 is attributed to the episodic nature of the ultra-orphan population, though momentum is building.
• Anthony Vendetti (Maxim Group): Asked about the sepsis Breakthrough Designation timeline and 2026 guidance updates.
  • Answer: The company plans parallel FDA discussions regarding the sepsis subpopulation analysis as enrollment concludes. 2026 guidance remains unchanged at $2M, with management expecting to exceed it; 2027 guidance to follow in early 2027.

Other Key Points:

• Dr. David Chung received the Combat Nephrology Award for contributions to renal support in high-acuity trauma and combat environments.
• The Neutralized AKI trial includes a pre-specified statistical analysis for the sepsis subpopulation, where over 70% of patients are expected to present with sepsis.
• The company is actively onboarding four new clinical sites with several more scheduled for activation by year-end to accelerate enrollment.
• No device-related adverse events were reported in the SAVE registry safety assessment across 50 treated pediatric patients.